Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.46 |
| ▸ | ADH1A | P07327 | 4/20 | 0.46 |
| ▸ | ADH1C | P00326 | 3/20 | 0.46 |
| ▸ | ADH7 | P40394 | 3/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908679 | 0.96 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL23377979 | 0.83 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL5933549 | 0.80 | HSD17B10 (0.33) | ADH1BADH1AADH1CMEN1KMT2A | |
| SCHEMBL10940490 | 0.80 | ADH1B (0.48) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL24508685 | 0.79 | ADH1B (0.40) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL25971297 | 0.78 | ADH1B (0.39) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL22794222 | 0.78 | ADH1B (0.39) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL24607375 | 0.77 | KDM4E (0.39) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL24002261 | 0.77 | KDM4E (0.39) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL433049 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096714-A | Antiviral compounds for the treatment of coronavirus, picornavirus and norovirus infections | 安力高医药股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| WO-2021097046-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | ADH1B 2494/4885ADH1A 1824/4885ADH1C 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.